Holen Sie sich die Stockscreener-App
9.35
0.11%
-0.010
Handel nachbörslich:
9.35
Schlusskurs vom Vortag:
$9.36
Offen:
$9.4
24-Stunden-Volumen:
229.94K
Relative Volume:
0.67
Marktkapitalisierung:
$306.67M
Einnahmen:
$65.42M
Nettoeinkommen (Verlust:
$-32.96M
KGV:
-7.3622
EPS:
-1.27
Netto-Cashflow:
$-19.87M
1W Leistung:
+0.00%
1M Leistung:
-10.18%
6M Leistung:
-33.40%
1J Leistung:
+22.22%
1-Tages-Spanne:
$9.15
$9.455
1-Wochen-Bereich:
$8.9688
$9.455
52-Wochen-Spanne:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Vergleichen Sie NPCE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
9.35 | 306.67M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
What analysts say about NeuroPace Inc. stockOutstanding capital appreciation - jammulinksnews.com
NeuroPace Inc. Stock Analysis and ForecastDynamic investment opportunities - jammulinksnews.com
What drives NeuroPace Inc. stock priceFree High-Return Strategy Alerts - jammulinksnews.com
Is NeuroPace Inc. a good long term investmentRapidly expanding wealth - jammulinksnews.com
NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey - MSN
NeuroPace secures $75M credit facility with MidCap Financial - MSN
(NPCE) Proactive Strategies - news.stocktradersdaily.com
What makes NeuroPace Inc. stock price move sharplyFree Investing Community - Newser
How NeuroPace Inc. stock performs during market volatilityFree Stock Selection - Newser
Why NeuroPace Inc. stock attracts strong analyst attentionFree Stock Market Query - Newser
NeuroPace appoints Patrick Williams as CFO - MSN
NeuroPace’s SWOT analysis: innovative epilepsy treatment stock faces growth hurdles By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, ... - Bluefield Daily Telegraph
NeuroPaceVolatile, Uncertain, But Promising (NASDAQ:NPCE) - Seeking Alpha
NeuroPace Inc (NPCE) Trading Down 3.93% on Jun 27 - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc.NPCE - WV News
NeuroPace stock maintains outperform rating at Leerink on expansion outlook - Investing.com
NeuroPace stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com UK
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm - WV News
NeuroPace's NAUTILUS Fallout: A Shareholder's Guide to Fraud Claims and Recovery - AInvest
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load? - simplywall.st
Metric Analysis: NeuroPace Inc (NPCE)’s Key Ratios in the Limelight - DWinneX
10 Best NASDAQ Stocks Under $50 to Buy - Insider Monkey
Two Sigma Investments LP Invests $293,000 in NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
Cantor Fitzgerald Comments on NeuroPace FY2026 Earnings - MarketBeat
Bank of America Corp DE Raises Position in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect - ACCESS Newswire
Research Analysts Set Expectations for NeuroPace Q2 Earnings - MarketBeat
NeuroPace Holds Virtual Annual Stockholders Meeting - TipRanks
NeuroPace’s SWOT analysis: med tech stock poised for growth amid challenges By Investing.com - Investing.com South Africa
NeuroPace’s SWOT analysis: med tech stock poised for growth amid challenges - Investing.com
NeuroPace Inc (NPCE) Shares Down 3.25% on Jun 12 - GuruFocus
Potential Securities Fraud: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) - ACCESS Newswire
NeuroPace stock maintains buy rating at UBS following physician survey By Investing.com - Investing.com India
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):